3/27
08:02 am
rani
Rani Therapeutics (RANI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
High
Report
Rani Therapeutics (RANI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
3/26
08:17 pm
rani
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/26
05:56 pm
rani
Rani Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Rani Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/26
04:39 pm
rani
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update [Yahoo! Finance]
High
Report
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update [Yahoo! Finance]
3/26
04:05 pm
rani
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
High
Report
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
3/25
04:53 pm
rani
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Medium
Report
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
3/19
04:55 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/19
04:05 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
3/17
12:20 pm
rani
Surf Therapeutics Reports Positive First-in-Human Data and Secures Additional Financing, Bringing Total Funding to $6M as Rheumatoid Arthritis Clinical Study Begins [Yahoo! Finance]
Low
Report
Surf Therapeutics Reports Positive First-in-Human Data and Secures Additional Financing, Bringing Total Funding to $6M as Rheumatoid Arthritis Clinical Study Begins [Yahoo! Finance]
1/28
10:48 am
rani
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer [Yahoo! Finance]
Medium
Report
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer [Yahoo! Finance]
1/28
07:00 am
rani
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
Medium
Report
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
1/9
08:02 am
rani
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
1/8
07:00 am
rani
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
Low
Report
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
12/30
04:14 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.